challenges in hiv treatment and care in a resource constrained environnement
DESCRIPTION
Challenges in HIV Treatment and Care in a Resource Constrained Environnement. Serge Paul Eholié Xavier Anglaret. Affiliation: ANRS research site in Côte d’Ivoire Infectious Disease Department, Treichville University Hospital, Abidjan Inserm U897, ISPED, Bordeaux University. INTRODUCTION. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/1.jpg)
1
Challenges in HIV Treatment and Care in a Resource
Constrained Environnement
Serge Paul EholiéXavier Anglaret
Affiliation:•ANRS research site in Côte d’Ivoire•Infectious Disease Department, Treichville University Hospital, Abidjan•Inserm U897, ISPED, Bordeaux University
![Page 2: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/2.jpg)
2
INTRODUCTION• In 1998-2001, pilot programs gave evidence that ART could
be feasible and effective in resource limited settings: – UNAIDS Initiative (Uganda, Côte d’Ivoire, Chile, Vietnam)– Countries (Senegal) or NGOS (MSF) initiatives
• From 2000 to 2010, large programs confirmed that ART was feasible and effective in resource limited settings: – As of june 2010, approx 6.6 million people on ART in low- and
middle-income countries (4.5 millions in sub-Saharan Africa); – With success in Scaling program and decentralization, almost 19 000 health facilities implemented;– With extensive evidence that ART reduces morbidity and
mortality in routine conditions.
![Page 3: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/3.jpg)
3
Successes of ART in low and middle income settings
![Page 4: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/4.jpg)
4
SUCCESSES
However, challenges remain!!!!
![Page 5: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/5.jpg)
5
Challenges to ensure the successof ART programs in low- and middle-income countries
* Increase coverage* Ensure financing sustainability * Reduce AIDS and HIV non-AIDS morbidity, and
mortality* Implement 2010 WHO guidelines* Improve assessment of programs efficacy* Improve prevention, diagnosis, and management of
adverse events* Improve retention* Ensure comprehensive HIV care
![Page 6: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/6.jpg)
6
CHALLENGE 1
Coverage
![Page 7: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/7.jpg)
7
Number of people receiving ART in december 2009
ART coverage in 2009, based on 2006 guidelines
ART coverage in 2009, based on 2010 guidelines
South Africa 971 556 56% 37%Kenya 336 980 65% 48%Nigeria 320 024 31% 21%Zambia 283 863 85% 64%Thailand 216 118 76% 67%Uganda 200 413 57% 39%Botswana 145 190 >95% 83%Cameroon 76 228 41% 29%Côte d’Ivoire 72 011 39% 28%
COVERAGE, December 2009: 36% in LMICIntraregional differences
Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010
![Page 8: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/8.jpg)
8
Challenge 2:Financing sustainability
80-95% of funds are from international donors
Achilles’ heel of ART programsSource Hecht R, Lancet 2010Courtesy of PM Girard
![Page 9: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/9.jpg)
9
CHALLENGE 3
REDUCE MORBIDITY AND MORTALITY
![Page 10: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/10.jpg)
ART MortalityCountries
* Zambia, Stringer JSA, JAMA 2006 * Senegal, Etard JF, AIDS 2006
* Zimbabwe, Erisktrup C, JAIDS 2007
* Haiti, Tuboi H, JAIDS 2009
* Honduras, Tuboi H, JAIDS 2009
Mortality rate
7%
23.1%
29.5%
12.4%
10.1%
![Page 11: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/11.jpg)
11
Risk factors for mortality
• Male sex• Clinical stage, WHO 3-4, CDC C• Body Mass Index <18-19 Kg/m2
• Haemoglobin<10g/dl• CD4 <200 cells/mm3
• Viral load >5 log10 copies/ml
Stringer JF JAMA 2006, Etard JF AIDS 2006, Erisktrup C JAIDS 2007, Moh R AIDS 2007, Tuboi SH JAIDS 2009, Mills EJ AIDS 2011,
Toure AIDS 2008, Lawn AIDS 2009
![Page 12: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/12.jpg)
12Severe P, N Engl J Med 2010
200-350 CD4/mL
< 200 CD4/mL
Mortality reduction 75%
![Page 13: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/13.jpg)
13
Challenge 3: REDUCE MORBIDITY AND MORTALITY
1) Certainly start ART earlier… but how much earlier ?
< 350 CD4 : minimal threshold worldwide1
< 500 CD4 : minimal threshold in increasing number of rich countries2,3
> 500 CD4 : ongoing randomized trials (START, Temprano4…)
2) Improve access to care, diagnosis and treatment of comon morbity (TB, bacterial diseases…)
1-WHO, Antiretroviral Therapy for HIV infections in adults and adolescents, Recommandations, 2010, h http://www.who.int ttp://www.who.int2- Prise en Charge Me´dicale des Personnes Infecte´es par le VIH Ministry of Health France, 2008. http://www.sante-sports.gouv.fr/3- Panel on Antiretroviral Guidelines for Adults, and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHHS, USA,20094- Temprano study ANRS 12 136, clinicaltrials.govNCT00495651
![Page 14: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/14.jpg)
14
Challenges 4
IMPLEMENT 2010 WHO GUIDELINES
![Page 15: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/15.jpg)
15
Main changes in WHO 2010 Guidelines
* Start earlier: CD4 < 350/mm3 or WHO stage 3,4
(vs. 200 CD4 or WHO stage 4 or WHO stage 3 & 200-350)
* First line regimen:
* Include viral load in routine monitoring
* Second line regimen:
WHO, Antiretroviral Therapy for HIV infections in adults and adolescents, Recommandations, 2010, h http://www.who.int ttp://www.who.int
![Page 16: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/16.jpg)
16
Main changes in WHO 2010 Guidelines
1) Start earlier: CD4 < 350/mm3 or WHO stage 3,4
(vs. 200 CD4 or WHO stage 4 or WHO stage 3 & 200-350)
* First line regimen:
* Include viral load in routine monitoring
* Second line regimen:
WHO, Antiretroviral Therapy for HIV infections in adults and adolescents, Recommandations, 2010, h http://www.who.int ttp://www.who.int
![Page 17: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/17.jpg)
17
ART at 350 CD4 vs. 200 CD4
Where to find patients at earlier stage of HIV disease ?
![Page 18: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/18.jpg)
18
ART at 350 CD4 vs. 200 CD4• Find patients with higher CD4 counts??• Increase Voluntary Counseling and Testing (VCT)• Facilitate or strenghten the link between
VCT centers and ART clinics• Anticipate and face an increase in the number of
patients on ART• Demonstrate cost effectiveness/acceptability to
governments and donors
![Page 19: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/19.jpg)
19Nash D, AIDS 2011
8 countries:3 Eastern Africa, 3 Southern Africa, 1 Western Africa,
1 Central Africa267 sites (ICAP centers)
121 404 patients
Median CD4136 cells/l
![Page 20: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/20.jpg)
20
ART at 350 CD4 vs. 200 CD4• Find patients wiht higher CD4 counts
– Change the paradigm – Target HIV negative patients
• Increase Voluntary Counseling and Testing (VCT)• Facilitate or strenghten the link between
VCT centers and ART clinics• Anticipate and face an increase in the number of patients on
ART• Demonstrate cost effectiveness/acceptability to governments
and donors
![Page 21: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/21.jpg)
21
ART at 350 CD4 vs. 200 CD4• Find asymptomatic patients
– Change the paradigm – Target HIV negative patients
• Increase Voluntary Counseling and Testing (VCT)• Facilitate or strenghten the link between
VCT centers and ART clinics• Anticipate and face an increase in the number of patients on
ART• Demonstrate cost effectiveness/acceptability to governments
and donors
![Page 22: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/22.jpg)
22
Insufficient time
Consent process
Lack of knowledge/training
Language
Lack of patient acceptance
Pre-test counselling requirements
Competing priorities
Inadequate reimbursement
Prenatal
24 barriersOther medical
settings
23 barriers
Why don’t physicians test for HIV? A review of the US littérature. Burke RC, AIDS 2007
Much of the failure to expand HIV Testing guidelines are related to physicians
![Page 23: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/23.jpg)
23
Standard of Care and Intervention periods in a routine HIV Testing Cohort in an out patient department, Durban, SA
Standard of Care(14 weeks)
Intervention(12 weeks)
Patients tested/offered, N (%)
HIV-infected patients, N (%)
HIV infection identified,
average N per week
137/435 (31.5%)
102/137 (74.5%)
8
1414/2912 (48.6%)
463/1414 (32.8%)
39
Bassett IV, JAIDS 2007
We need a pro-active approach!!!!
![Page 24: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/24.jpg)
24
ART at 350 CD4 vs. 200 CD4• Find asymptomatic patients
– Change the paradigm – Target HIV negative patients
• Increase Voluntary Counseling and Testing (VCT)– HIV testing is general medicine (« it’s all HCW business »)– Make rapid tests available
• Facilitate or strenghten the link between VCT centers and ART clinics
• Anticipate and face an increase in the number of patients on ART
• Demonstrate cost effectiveness/acceptability to governments and donors
![Page 25: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/25.jpg)
25
ART at 350 CD4 vs. 200 CD4• Find asymptomatic patients
– Change the paradigm – Target HIV negative patients
• Increase Voluntary Counseling and Testing (VCT)– HIV testing is general medicine (« it’s all care workers business »)– Make rapid tests available
• Facilitate or strenghten the link between VCT centers, Ante Natal Clinic and ART clinics
• Anticipate and face an increase in the number of patients on ART
• Demonstrate cost effectiveness/acceptability to governments and donors
![Page 26: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/26.jpg)
26
ART at 350 CD4 vs. 200 CD4• Find asymptomatic patients
– Change the paradigm – Target HIV negative patients
• Increase Voluntary Counseling and Testing (VCT)– HIV testing is general medicine (« it’s all care workers business »)– Make rapid tests available
• Facilitate or strenghten the link between VCT centers and ART clinics
• Anticipate and face an increase in the number of patients on ART
• Demonstrate cost effectiveness/acceptability to governments and donors
![Page 27: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/27.jpg)
27
<200
% ELIGIBLE<250 (2008 criteria)
%ELIGIBLE<350
%ELIGIBLEAge 15-24 25+
22.4%41.5%
25.9% (1,15 increase)51.1% (1,24 increase)
41.4% (1,85 increase)63.1% (1,53 increase)
Sex Female Male
35.2%37.5%
43.4% (1,23 increase)40.5% (1,20 increase)
57.2%(1,63 increase)55.0%(1,47 increase)
Overall 35.7% 43.7% (1,23 increase) 56.8% (1.59 increase)
Source: Konde-Lule J, AIDS Care 2010
< 350 vs <200 = 59% increase in demand of services
![Page 28: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/28.jpg)
28
Adjusted HR(95% CI)
p
Patient volume Low (reference) Medium High
-1.40 (1.03-1.92)1.34 (0.95-1.89) 0.47
Clinical Staff Burden Low (reference) Medium High
-1.01 (0.78-1.32)1.02 (0.69-1.52) 0.91
Pharmacy Staff Burden Low (reference) Medium High
-1.68 (1.29-2.19)2.63 (1.70-4.06) < 0.001
Patients Volume, Human Resources Levels and Attrition from HIV Treatment Programs in Central Mozambique
Lambdin BH, JAIDS 2011
Staff burden : do not forget those who deliver the pills !(200-300 patients/day or more !!!!)
![Page 29: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/29.jpg)
29
ART at 350 CD4 vs. 200 CD4• Find asymptomatic patients
– Change the paradigm – Target HIV negative patients
• Increase Voluntary Counseling and Testing (VCT)– HIV testing is general medicine (« it’s all care workers business »)– Make rapid tests available
• Facilitate or strenghten the link between VCT centers and ART clinics
• Anticipate and face an increase in the number of patients on ART– Set up or strenghten task shifting
• Demonstrate cost effectiveness/acceptability to governments and donors
![Page 30: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/30.jpg)
30
ART at 350 CD4 vs. 200 CD4• Find asymptomatic patients
– Change the paradigm – Target HIV negative patients
• Increase Voluntary Counseling and Testing (VCT)– HIV testing is general medicine (« it’s all care workers business »)– Make rapid tests available
• Facilitate or strenghten the link between VCT centers and ART clinics
• Anticipate and face an increase in the number of patients on ART– Set up or strenghten task shifting
* Demonstrate benefits and cost effectiveness for acceptability by governments and donors
![Page 31: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/31.jpg)
31
CD4<200 CD4<350 Difference
P-Y of ART 40 752 534 61 292 374 + 20 539 839 (+ 50%)
* AIDS/ deaths
8 180 609 6 501 483 - 1 679 126 (- 21%)
* Life years
162 032 903 163 012 351 + 979 448 (+ 1%)
* New HIV infections
11 198 013 9 946 912 - 1 251 101 (- 11%)
Source: Stover J, AIDS Research and Treatment 2011
Benefits on morbidity, mortality and transmission
Cost effectiveness: Walensky R, Ann Intern Med 2009
![Page 32: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/32.jpg)
32
Main changes in WHO 2010 Guidelines
1) Start earlier : CD4 < 350/mm3 or WHO stage 3,4
(vs. 200 CD4 or WHO stage 4 or WHO stage 3 & 200-350)2) First line regimen:* Include viral load in routine monitoring* Switch when VL>5,000 copies/ml (vs. >10,000 copies/ml in
2006 guidelines)* Second line
* Stop ABC+ DDI. * AZT/TDF+XTC+ATVr/LPVr
* Start as soon as possible in case of tuberculosis and HVB
![Page 33: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/33.jpg)
33
Challenges for first line regimen
* Costs * Phase out d4T* Choice between AZT and TDF
- Haematological toxicity, LD (AZT)- Renal safety, bone mineral toxicity (TDF)
* Choice between efavirenz and nevirapine- Percentage of young women, pregnancy (NVP)- One pill, once a day, TB co-morbidity (EFV)
* Availabililty of fixed drug combination* Paediatric formulation
Cost, efficacy, cost-effectiveness and tolerance issues
![Page 34: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/34.jpg)
34
Phase out stavudine : issues* Lingering stocks of d4T - 30 countries have implemented d4T phase out plan (12/2009)
- 60% first line started with d4T (12/2009)
* Finance constraints – TDF or ZDV first line 2-3 times as high as d4T regimen– … at a time when we still need to scale up the number of
people initiating ART
Need for :- Further drug price reductions (AZT and TDF)
- Increase funds for ART programme
Renaud-Thery F, AIDS Res and treatment 2011
![Page 35: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/35.jpg)
35
Bendavid E, AIDS 2011
WHO MEETING REPORT. Short-Term Priorities for Antiretroviral Drug Optimization, London UK, 18-19 avril 2011.
![Page 36: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/36.jpg)
Prevalence of Renal dysfunction in HIV-seropositive untreated patients in Sub saharan Africa
* Nigeria (n=400) Emen CP, Nephrol Dial Transplant 2008
* South Africa (n= 1322) Brennan A, AIDS 2011
* Zambia (n=24 596) Mulenga BL, AIDS 2008
* Msango L (n=335) AIDS 2011
38%
35.7%
33.7%
63.6%
36HIV is THE kidney killer (not tenofovir)
![Page 37: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/37.jpg)
Incidence of severe renal dysfunctionDART (n=3316) eGFR < 30ml/mn
* Median time to severe renal dysfunction14 weeks IQR [4-52]
* TDF 41/2469 (1.7%)* NVP (Open-label) 4/247 (1.6%)* ABC (Nora Study) 3/300 (1.0%)* NVP (Nora Study) 4/300 (1.3%) Reid A, Clin Infect Dis. 2008
P=0.94
* Zambia, 30/960 (3.2%), M12 (Chi BH, JAIDS 2010)
* Lesotho, 31/566 (5.5%), M12 (Bygrave H, Plos One 2011)
![Page 38: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/38.jpg)
38
Follow WHO guidelines for tenofovir prescription
* Creatinine dosage (creatinine clearance calculation)* Proteinuria with urines sticks
![Page 39: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/39.jpg)
39
Main changes in WHO 2010 Guidelines
1) Start earlier : CD4 < 350/mm3 or WHO stage 3,4
2)°First line:
3) Include viral load in routine monitoring
* Second line
WHO, Antiretroviral Therapy for HIV infections in adults and adolescents, Recommandations, 2010, h http://www.who.int ttp://www.who.int
![Page 40: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/40.jpg)
40
Case for routine use of viral load
* Best tool to assess adherence
* Maintain first line therapy
* Earlier switch to second line limit NRTI and
NNRTI cumulative resistance;
* Cost effectiveness
![Page 41: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/41.jpg)
41
Status at 12 months of ART :
Messou E, JAIDS 2010
![Page 42: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/42.jpg)
42
Case for routine use of viral load
* Best tool to assess adherence
* Maintain first line therapy
* Earlier switch to second line limit NRTI and
NNRTI cumulative resistance;
* Cost effectiveness
![Page 43: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/43.jpg)
M6N=996
M12N=925
Undectable VL 799 (80.2%) 693 (75%)
Detectable VL
Resistance ≥ 1 mutation
197 (19.8%)
7%
232 (25%)
11%
Messou E, JAIDS 2010
Interest of early viral load (M4-M6) Interventions to reinforce adherence, maintain first line
Half of patients with detectable viral load at 12 months have no resistance mutations
![Page 44: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/44.jpg)
44
Case for routine use of viral load
* Best tool to assess adherence
* Maintain first line therapy
* Earlier switch to second line limit NRTI and
NNRTI cumulative resistance; Keiser et al, AIDS 2011
* Cost effectiveness
![Page 45: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/45.jpg)
45
Case for routine use of viral load
* Best tool to assess adherence
* Maintain first line therapy
* Earlier switch to second line limit NRTI and
NNRTI cumulative resistance;
* Cost effectiveness
![Page 46: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/46.jpg)
46
Relative increase in Life Expectancy (vs. only one line
of ART)
Incremental Cost
Effectiveness Ratio1
($ US/LYS)
Incremental Cost
Effectiveness Ratio2
($ US/LYS)
Switch to 2nd line on :
- WHO stage 3-4 event 24.3 1670 1670
- 50% in peak CD4 46.4 2120 Dominated
- HIV RNA*, 1 log or return to pretreatment HIV-RNA
61.3 2280 1990
Source: Kimmel AD,JAIDS 20101 HIV RNA Tests Cost 87 USD2 HIV RNA Tests Cost 25 USD
![Page 47: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/47.jpg)
47
Challenges for use of viral load in RLS* Affordability (once again… costs…) :
- Advocacy (same as before with ARV drugs)
- Generics tests
* Availability in rural settings:
- Point of care
- Dried Blood Spot
- Power (electricity)
- Maintenance Rouet F and Rouzioux C, Expert Rev Mol Diagn 2007Calmy A, AIDS 2008
![Page 48: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/48.jpg)
48
Main changes in WHO 2010 Guidelines
1)Start earlier : CD4 < 350/mm3 or WHO stage 3,4
2) First line:
«3) Include viral load in routine monitoring
4) Second line
![Page 49: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/49.jpg)
49
Challenges for second line* Costs* Time to switch to second line in patients failing 1st
line* Effective NRTI backbone* Place of drugs already ordered or used (ABC/ddI)* Fixed Drug Combination or co-blister* Availability of ritonavir heat stable capsule* Use in TB co-infected patients * Forecasting (Renaud-Thery F, AIDS Res and Treatment 2011)
![Page 50: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/50.jpg)
50
Regimen Low incomecountries
Middle IncomeCountries
d4T + 3TC + NVP $ 89 $ 88 AZT + 3TC + NVP $ 149 $ 226AZT + 3TC + EFV $ 220 $ 281TDF + 3TC + EFV $ 210 $ 268TDF + FTC + EFV $ 255 $ 325TDF + 3TC + NVP $ 190 $ 243AZT + 3TC + LPV/r $ 585 $ 1150TDF + 3TC + LPV/r $ 590 $ 1070TDF/AZT + 3TC + ATV/r $ 395/465
ARV cost per patient per year
Sources: WHO/UNAIDS/UNICEF, Clinton Foundation Health Access Iinitiative, MSF
![Page 51: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/51.jpg)
51
76.5% LPV/r45% suboptimal NRTI regimen??
1.4% of adults receiving ART
Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector Progress report 2010
![Page 52: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/52.jpg)
52
Challenges for second line* Costs* Time to switch to second line in patients failing 1st
line Keiser et al, AIDS 2011
* Effective NRTI backbone* Place of drugs already ordered or used (ABC/ddI)* Fixed Drug Combination or co-blister* Availability of ritonavir heat stable capsule* Use in TB co-infected patients * Forecasting (Renaud-Thery F, AIDS Res and Treatment 2011)
![Page 53: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/53.jpg)
53
Second line efficacy in LMIC* South Africa (n= 1648)* 46% failure > 6 months FU
Factors associated
* Cambodgia** (n=70, all LPV/r) 15% VL failure, FU 24 months
* Thailand (n=95) 2nd line based on genotype test: VL failure 15% (M24), 10% (M36);
Pujades-rodriguez M, Jama 2010
Low CD4 cells counts Suboptimal regimen (NRTI +++)
Ferradini L, J Int Aids Soc 2011
May Myat W, J int Assoc Phys Aids Care 2011
* MSF programs, ** ESTHER
![Page 54: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/54.jpg)
54
Challenges for second line* Time to switch to second line in patients failing 1st line* Costs* Effective NRTI backbone* Place of ABC and ddI* Fixed Drug Combination or co-blister* Availability of ritonavir heat stable capsule* Paediatric formulation* Use in TB co-infected patients * Forecasting
Renaud-Thery F, AIDS Res and Treatment 2011
![Page 55: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/55.jpg)
55
Challenge 5
Third line: Salvage Therapy in LMIC
1-5% or more??
![Page 56: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/56.jpg)
56
Challenges for Third Line
* Cost of darunavir, raltegravir, and etravirine
* Use of genotype test: necessary or essential?
* Assessment of real needs
* Pilot studies assessing : resistance patterns in patients
failing 2nd line, place of adherence reinforcement,
adherence efficacy and tolerance of third line drugs…
(ANRS third line trial in 5 west african countries)
![Page 57: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/57.jpg)
57
Comparaison of prices for ART regimen according to line of treatment
MSF, Antiretroviral Therapy price reductions, 13th edition, July 2010
X 7
![Page 58: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/58.jpg)
58
Challenges for Third Line
* Cost of darunavir, raltegravir, and etravirine
* Place of genotype test: necessary or essential?
* Set up pilot studies assessing resistance patterns
in patients failing 2nd line, place of adherence
reinforcement, efficacy and tolerance of third line
drugs… (ANRS third line trial in 5 West African
countries, 1 South East Asian country)
![Page 59: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/59.jpg)
59
Challenge 6
Long term issues :
• Improve monitoring• Ensure long term adherence• Prevent and take care of long-term toxicity• Diagnose and treat HIV non-AIDS morbidity
![Page 60: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/60.jpg)
60
ART laboratory monitoring (WHO 2010) Phase of HIV Management
Recommended Test
Desirable Test
At HIV diagnosis CD4 HBs Ag, anti-HCV?Pre ART CD4
At start of ART CD4 Hb for AZT1
Creatinine clearance for TDF2
ALT for NVP3
On ART CD4Hb for AZT1
Creatinine clearance for TDF2
ALT for NVP3 At clinical failure CD4 Viral loadAt immunological failure Viral load
1 Recommended test in patients with high risk of adverse events associated with AZT (low CD4 or low BMI).
2 Recommended test in patients with high risk of adverse events associated with TDF (underlying renal disease, older age group, low BMI, diabetes, hypertension and concomitant use of a boosted PI or nephrotoxic drugs).
3 Recommended test in patients with high risk of adverse events associated with NVP ( ART naive HIV+ women with CD4 > 250 cells/mm3, HCV co-infection)
![Page 61: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/61.jpg)
61
![Page 62: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/62.jpg)
62
Long term monitoring issues We need tests for :
• Metabolic syndrom…
• Renal function …
• Bone Mineral density …
• Cardio-vascular assessment …
• Malignancies diagnosis …
![Page 63: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/63.jpg)
63
Challenges for long term follow-up • HIV and ageing: 3 millions HIV
individuals >50 years in sub-Saharan Africa (14% of overall HIV adults)
• Access to treatment for: malignancies, cardiovascular diseases/neurological diseases, diabetis, dyslipidemia, renal insufficiency …
Mills EJ, Lancet Infect Dis 2010Negin J, JAIDS 2010Nakimuli-Mpungu E, Neurobehavioral HIV Medicine 2011
![Page 64: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/64.jpg)
64
Challenges 7
ENSURE COMPREHENSIVE HIV CARE
![Page 65: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/65.jpg)
Percentage of household expendituresNon ARVs and non CD4 costs among patients receiving ART
Cameroun1 Côte d’Ivoire2
Health expenditures
Medical visits and others
Transportation
20 USD/month
44%
12%
24.3 USD/month
50%
25%
65
1- Boyer S, Bull WHO 2010
2- Beaulière A, PLoS ONE 2010
![Page 66: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/66.jpg)
66
Challenges 8
IMPROVE RETENTION
![Page 67: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/67.jpg)
67
Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010
![Page 68: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/68.jpg)
68
* Serious barriers - Transport costs - Time needed for treatment - Logistical challenges
* Less influencal factors - Stigma around HIV/AIDS - Side effects
Patients’ perception
![Page 69: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/69.jpg)
69
1) Set up and maintain simple standardized monitoring systems
2) Reliably ascertain true treatments outcomes3) Reduce death rates4) Ensure uninterrupted drugs supplies5) Use simple, non toxic and free ART-regimens6) Decentralized ART clinics and reduce frequency of visits7) Reduce indirect patients costs8) Strenghten ART-links within and between health services
and the community9) Use ART-services to deliver other useful interventions10) Innovative (tining out of the box intervention)
Harries AD, Trop Med Intern Health 2010
![Page 70: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/70.jpg)
Challenge 9: Human resources* Motivation: Increase salary
* Struggle the brain draining of health care workers to national
or international NGOs (disparities)
* Cure an emerging disease, « the perdiemitis »
(Ridde V, Trop Med Int Health 2010)
* Set up the task shifting
(monitoring ART: nurses vs doctor, 1.09 (95% CI 0.89–1.33)
(Sanne I, CIPRA Study-South Africa, Lancet 2010)
70
![Page 71: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/71.jpg)
71
Challenges 10
Earthquake (Haiti)Floads
Dryness and Food crisis (eg; East Africa)Socio-political crisis (Eg:Côte d’Ivoire)
Out-of-controlHumanitarian crisis
Jeopardize 10-15 years of successes! !
![Page 72: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/72.jpg)
72
http://www.lemonde.fr/idees/article/2011/04/05/l-attention-aux-malades-du-sida-barometrede-l-humanite_1502634_3232.html
“Justice must prevail against those who exploit patients as political weapons and thereby undermine years of human rights progress. Much has been said and written about the need to treat as war crimes all failures to protect civilians during conflict. Obstructing access to needed medical care should rank high among these.”
![Page 73: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/73.jpg)
73
Conclusion
![Page 74: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/74.jpg)
74
« A perpetual challenge will be living up with the commitment and courage of those who went before- health care workers, scientists, and affected persons- who faced the unknown and took risks. In general 30 years of AIDS confirm that there is indeed « more to admire in men than to despise »
![Page 75: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/75.jpg)
75
Courtesy of S Matheron
![Page 76: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/76.jpg)
76
Acknowledgements* E Bissagnéné
* A Calmy
* JF Delfraissy
* DK Ekouevi
* PM Girard
* C Kouanfack
* PS Sow
* M Vitoria
![Page 77: Challenges in HIV Treatment and Care in a Resource Constrained Environnement](https://reader036.vdocuments.net/reader036/viewer/2022062520/5681654a550346895dd7c17d/html5/thumbnails/77.jpg)
77
Grazie Merci
ChoukranThank you
Obrigado
Mo
Dieureudieuf Djaraman
Asanti
I ni tché
M"pussda barka
Bondodi
AkpéNgiyabonga
Mo Pi Wo
Amesegnalehu
Gracias